Q3 2023 Affimed NV Earnings Call
Yeah.
Good day, and thank you for standing by and welcome to <unk> N V third quarter 2023 earnings and business update conference call. At this time all participants are in a listen only mode. After the speaker's presentation there'll be a question and answer session to ask a question. During the session you will need to press star one.
One on your telephone you will then hear an automated message advising your hand. This race to withdraw your question. Please press star. One again, please be advised that today's conference is being recorded I would now like to hand, the conference over to your speaker today, Alex would Akitas head of Investor Relations. Please begin sir.
Thank you Norma and thank you all for joining us today for third quarter 2023 update call before we begin I'd like to remind everyone that he issued the relevant press release earlier today, which can be found on the Investor Relations section of our website.
The presentation is also on the website on the call today, we have the members of our management team, including our Chief Executive Officer, Andreas <unk>, Our Chief Medical Officer, Orange to failures like scientific Officer, Wolfgang Fischer Chief operating officer.
And Angus Smith, our Chief Financial Officer.
Team will be available for Q&A. After the prepared remarks before we start I would like to remind you that today's presentation contains projections and forward looking statements regarding future events. These statements represent our beliefs and assumptions only as of the date of this call except as required by law we assume.
No obligation to update these forward looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in the forward looking statements, even if new information becomes available in the future. These forward looking statements are subject to risks and uncertainties.
Actual may differ materially from those expressed or implied in these statements.
Various factors, including but not limited to those identified under the section entitled risk factors in our filings with the SEC and those identified under the section entitled forward looking statements in the press release that we issued today and filed with the SEC with that I'll turn the call over.
Hi, Eddie.
Thank you Alex and good day everyone.
Thanks for joining us today also from my side.
We have entered a very important and exciting phase Barack limit our investors and patients that do require a novel options in order to prolong their lives. So that they can spend more time with their family and friends.
We have been progressing well with all three Kennedy program.
And are allowing a peer we get why we plan to report data frequently over the next weeks.
Yes.
Moving to slide five we recently announced that the new named who are aged from 13 will.
Symptomatic if developed in combination with our Tivo, our NK program in the aluminite towards we study.
We're now actively recruiting hodgkin lymphoma.
Shlomi noise two or three.
And preparing to report.
Efficacy and safety data from this study in.
In the first half.
As a reminder, during this phase of the study we will be treating 24 patients with hodgkin lymphoma or core.
And all these courts will use active doses of that time to make an outlook.
Yeah.
In addition, our interactions with FDA FDA has been very productive.
In September we announced that we received fast track designation and.
Today, we announced that we received positive feedback from the FDA in their responses for our type C meeting, which Andrea will discuss in just a moment.
Okay.
But from the Fda's written responses, we believe that the aluminum two or three study designed based on FDA feedback and guidelines puts us in a very good position to pursue accelerated approval.
The aluminite two or three study built on the.
Unprecedented results observed in <unk> from 13, one O for the investigator sponsored clinical trial, we have been running in collaboration with Amgen.
Updated data from that study will be presented by Dr. Anthony at all.
The lead investigator.
The Ash meeting annual meeting 2023 in Houston on December 11.
A female alchemy will house the dedicated code for the financial community to provide an in depth insight into this important update which will include all my follow up data.
Now turning to April 24, we remain on track to provide an update on the first three expansion cohorts from the combination study of <unk> hundred 24, with Anthony to lease them up in December.
This combination is based on findings from 2000 and activate both innate and adaptive immune cells.
And the idea now is to enhance the efficacy by combining <unk> and 'twenty.
Awesome.
As a reminder, we already have seen that our naphthalene data that symptom in combination with PD. One is able to double the complete response rate of PD, one alone in Britain refractory Hodgkin lymphoma patients.
During the third quarter, we also initiated enrollment in the north north of lung cancer, Egfr mutant cohort and have begun treating patients.
Again as a reminder April 24 at the single agent showed partial responses in durable stable disease in this indication.
Data from this expansion cohort is expected in the first half of 2020.
And lastly, we continued to make good progress in our April 28 monotherapy.
Aspiration.
During the third quarter, we completed treatment of patients in the third dose cohort without any limiting doses.
<unk> and completed enrollment of patients in the fourth dose cohort now administering a flat dose to really ground beauty.
On slide seven we provide important background on the treatment of the indications we're targeting with luminous towards me.
In Hodgkin lymphoma.
BB and PD, one checkpoint inhibitors have changed the way patients are treated.
As these therapies move to earlier lines of therapy.
Therapy.
Patient population with high unmet medical need has emerged.
BV and PD, one tablet refractory population.
Now, let me quickly talk about which therapies exist in general for relapsed refractory Hodgkin lymphoma.
For this patient patient populations cytotoxic agents.
Lastly, chemo and bendamustine or even targeted agents such as lean a little micro inventory inhibitor unlisted in the NCC in guidelines.
It's important to note that these therapies with study in relapsed refractory Hodgkin patients.
Before the introduction of EV and checkpoint inhibitors.
And limited information is available on their efficacy.
In the double refractory population.
But even still the correct correct <unk>.
For peers.
We believe this is where a symptomatic lap NK cell therapy has the potential to transform the treatment landscape for double refractory patients.
Their response rates reported from a from 13, one of the 104 outstanding and in particular, a CR rate of 70 plus percent is higher than the CR rate of other treatment.
Heavily pre treated.
And that's next month will provide.
A definitely view on the duration of response and event free survival for the therapy for HL patients treated at the recommended phase.
Newmanize two of three further intuit's relapsed refractory PTC outpatient.
<unk>.
Very high need with more than half of patients moving into second line.
Which now offers only agents with limited efficacy and still no.
Based on our market results, we believe the market.
Our attempts to make last NK cells and <unk>.
Double refractory Hodgkin lymphoma alone.
Net of $1 billion.
And with the inclusion of second line relapsed refractory PCL.
Would increase to over 3 billion combined.
Finally during the quarter, we thought significant reduction in our operating cash burn.
It's going to the first two quarters this year.
So the actions we implemented during the first half of the yet to focus our investments on our preclinical program.
With that I'll turn the call over to Andrea who will provide additional insight on the progress we're making in our pipeline.
Andrea.
Thank you.
Also while it come from my side to every side of everyone on the phone.
I would like to start my clinical overview with our progress that we've made with AFM 13, as Eddie said now caught a same can make going forward.
We are pleased to update you on the progress that we have made regarding the development of <unk> in combination with allo NK or is it also known as <unk> 101 from our Tivo.
After receiving clearance from FDA to proceed with the initiation of the phase two clinical trial earlier this year.
We made significant progress towards our goal of getting the study up and running.
And we now have the first sites open and we are actively recruiting patients.
Furthermore, as shown on slide nine.
In September we received fast track designation.
For a symptomatic and in October we got a retrofit break from FDA on our AR.
Type C meeting request.
On slide 10, we show the updated Lumi Nice study design.
In accordance with Fda's feedback, we were now at a cohort to the lemon lives two or three trial.
Which will treat patients with relapsed or refractory Hodgkin lymphoma.
With Allo, NK plus IL two only.
This will address the contribution of individual components in the combination.
Fifth cohort will be designed as an observation cohort with the option available to patients to cross over to the combination with symptomatic.
<unk> said don't show a response to their initial treatment.
We believe that the study which was designed based on Fda's recommendation on guidelines.
Puts us on track for regulatory approval pending the final assessment of the magnitude of clinical benefit.
We are very encouraged with the outcome of the FDA interactions.
And look forward to continuing our discussions with the agency.
Yes, we are generating data from the study.
As announced we expect to report initial safety and efficacy data from this trial during the first half of 2024.
In addition, as you mentioned, Dr. Yao Glen Nickle relate investigator of the original study.
That investigators are combination of symptomatic with cord blood derived NK cells at MD Anderson cancer Center.
We presented updated data in an oral presentation at Ash 2023 annual meeting.
On December 11.
The abstract for the presentation was published earlier this month.
As shown on slide 11.
Cutoff date for the abstract a total of 42 relapsed refractory Cds 30 positive Hodgkin lymphoma, and non Hodgkin lymphoma patients.
In this study.
36 of six patients treated at the recommended phase II dose.
Important to mention that all patients were heavily pretreated.
And refractory to their most recent line of therapy.
With active progressive disease at the time of enrollment.
Of note.
All of the Hodgkin lymphoma patients with double refractory to BV and PD one.
The combination treatment achieved an overall response rate of 94, 4% with a complete response rate of 72, 2% at the recommended phase II dose.
So treatment regimen continues to demonstrate a good safety and Tolerability profile.
With no cases of cytokine release syndrome.
Immune effector cell associated neurotoxicity or graft versus host disease of any great.
At a median follow up of 14 months.
The overall survival rate was 76%.
And so the overall median overall survival has not been reached.
And then in depth analysis included updated.
Event free survival and overall survival data will be presented during the upturn yet of oral presentation.
Including a comprehensive analysis of the efficacy durability and safety outcomes.
Demonstrating the potential of a simpler make in combination with allogeneic NK cells.
On the same day <unk> plans to host an investor call to provide additional information.
What's the status of Illumina is two or three study the treatment landscape in Hodgkin lymphoma, and peripheral T cell lymphoma, and so irrespective of market opportunities.
Now, let me turn to Ias 24.
As Sloan I'm, sorry, slide 12.
In the ongoing study.
<unk> for one or two.
We are treating patients with <unk> 24, and it is really sort of map.
And the ongoing studies the original three cohorts, including patients with non small cell lung cancer Egfr Wild type <unk>.
Strict and gastroesophageal junction adenocarcinoma.
And pancreatic capitals cellular in biliary tract cancer, respectively.
Based on the promising activity seen with air from 24 in our monotherapy study.
We added also in cohort four egfr mutant non small cell lung cancer patients.
That is now actively treating patients.
We believe that a year from 2000 and false roll in activating the immune system by specifically, triggering NK cells and macrophages to destroy tumor cells and deliberate tumor associated antigens is crucial.
These antigens can be processed by macrophages and dendritic cells with a possibility to activate tumor reactive T cells.
The combination of air from 'twenty, four which activates the innate immune system with a test Silesia map, which impacts the adaptive immune system. Therefore has in our opinion a very good logical rationale.
As Eddie mentioned, we will report data on the first three cohorts.
Of 10 to 15 patients per cohort in December.
And we plan to report data on the non small cell lung cancer Egfr mutant cohort in the first half of 2024.
If we turn it to AFM 28 on Slide 13, we show the progress for our third clinical program.
From 2008 is targeting CD 123 in acute myeloid leukemia.
Is this program we have completed treatment of patients in the third dose cohort of our ongoing and.
Dose escalation trial.
Using a dose of 100 milligram flat once weekly.
As mentioned, we have not seen any dose limiting toxicities at this dose cohort and we Meanwhile have completed the enrollment of patients in dose cohort for treating patients at 200 milligrams weekly.
Now where do we go from 28.
So first step is to complete the dose escalation study and to identify a safe recommended phase two dose based on correlated science and initial clinical activity.
After that for US there are two options either to develop I hear from 28, a single agent or in combination with allogeneic NK cells.
We are planning to provide so next progress update on this during the first half of next year.
Well. Thank you again for your intention and with this I will turn over the call to Angus to update you on our quarterly financial performance Angus. Please.
Thank you Andreas.
Balance sheet and income statement highlights are shown on slides 15, and 16 of the presentation.
A quick reminder, that <unk> consolidated financial statements have been prepared meals with <unk> as issued by the international accounting standard board or SP. The.
The consolidated financial statements are prepared in euros.
Since our financials are described in detail in the press release, we issued this morning I will only provide highlights on this call.
As of September 32000, 2023, cash cash equivalents and financial assets totaled $97 5 million compared to 193 million euros on December 31 2022.
Based on our current operating plan and assumptions, we anticipate that our cash and cash equivalents.
Along with our financial assets will support operations into 2025.
Net cash used in operating activities for the quarter ended September 32023 were $18 2 million euros compared to 19 million for the third quarter of 2022 importantly, our operating cash burn for the quarter reflected a 45% drop from the previous quarter and is reflective of our efforts to carefully manage our cash burn going forward.
Cash flow from investing activities for the quarter reflects the fact that we allocated a portion of our cash resources to short term government bonds during the quarter in an effort to diversify and get access to higher interest rates on our excess liquidity.
Total revenue for the quarter ended September 32023 was 2 million compared with $14 9 million for the quarter ended September 32022.
Total revenue predominantly relates to the ROI math, and genentech collaborations and the reduction as compared to the prior year period is due to the fact that we have now completed our obligations under both collaborations and therefore recognized a significant majority of the associated revenue.
We remain eligible for future milestone payments under both collaborations based on the advancement of the licensed molecules, which is at the discretion of our partners I will now turn the call back to Ali for closing remarks.
Thank you Angus.
Let's move to slide 18.
You see the details of our upcoming milestones for one of our programs.
This is Andy mining true, we have entered a very important and exciting phase.
Whereas the document.
Our investors and in particular patients that do require a novel options in order to prolong prolong their lives.
To be able to spend more time with their families and friends.
We have been progressing well with all our <unk> program.
And arent in this area to where we planned to frequently report data over the next weeks and months.
Thank you all for your continued support and trust in our mission to make a difference in the lives of patients.
We look forward to sharing more exciting developments with you in the very near future.
We're now ready to take questions operator.
Thank you.
As a reminder to ask a question you will need to press star one on your telephone to withdraw your question. Please press star one again, please wait for your name to be announced please standby, while we compile the Q&A roster.
Our first question please.
Our first question comes from the line of Maury Raycroft.
Of Jefferies. Your line is now open.
Hi, This is James on for Maury, Congratulations on the progress and thank you for taking our questions.
For the type C meeting did the FDA provide any more specifics on the magnitude of clinical benefit.
And do they seem more focused on or or or durability measures and then after I have a quick follow on.
Andreas do you want to take that question. Please.
I can take it all Wolfgang who I think is also on the line but.
I can probably start.
So no.
As you May know when you talk with FDA. They would never give you a fixed number of what I consider.
Meaningful magnitude of effect.
However, when we look at the landscape and when we talk to key opinion leaders, whom we have.
Done quite quiet quite a number of interviews right now.
Thanks, a consensus seems to focus on 50%.
Response rate or higher was the majority of responses being complete responses.
And when you look at a time related factors I think it's probably duration of progression free survival of six months or longer for these very heavily pre treated patients.
Patients now again I have to stress. This is more feedback from key opinion leaders FTA will always tell you. It's a revenue issue.
And we expect that FDA will look both at overall response rate as well as time related affect us like as a duration of response or event on progression free survival.
I hope this addresses your question.
Yes, that's helpful.
And the second question is how many patients in follow up do you need to adequately address the contribution of single.
Ponant in the Allo NK IL two cord that you reported today.
Again that is a question that basic or probably will be answered by the data.
We expect that the response rate for a non target.
NK cells will be relatively low so we will see or we expect to see already a very significant differences in the response rates, which.
Clearly we'll keep.
The importance of long term follow up.
You only have a couple of responses.
Compared to a response rate, which was in excess of 50% to 60%.
Essentially it's the magnitude of differences would be sufficient.
So how many patients do you think you would need.
Again this is something that we will discuss further with FDA all of the <unk>.
Initial design is somewhere between 10 and 20 patients.
Great. Thank you so much for answering my question I'll hop back in the queue.
Yeah.
Thank you one moment for our next question. Please.
Our next question comes from the line of Devin conduct with <unk> Securities. Your line is now open.
Hey, guys. Thank you so much.
Oh I have actually a follow up on the previous question.
And just to confirm was there any changes to the protocol that the FDA asked for and just broadly.
Hotel based on the type C meeting can you move ahead with part two of the study are all on one is there any need to.
Meet with the FDA again, I know you guys have.
No.
You can have multiple meetings with the FDA given your designation fast track designation.
Okay.
Texas as well or do you want to take.
I can take it.
Hi.
So the first the first question, whether there have been changes to the protocol requested by the FDA. The answer is no.
This MKS mentioned before we are going to add this one cohort allo NK cells alone.
That's the first question and the second question there is no need for us to build backup consult with the FDA to proceed with our study so that means we can proceed.
The beginning to the end as approved by the FDA.
Got it and also just another clarification isn't it.
Allo and CAD two cohort needed.
For accelerated approval submission.
When we when we spoke to the FDA during during our <unk> process and also train type C U E.
The contribution of single components is important to the HFC and therefore, the assumption is yes. This is something which we need to get accelerated approval.
Great. Thank you so much.
The work.
Thank you one moment for our next question. Please.
Our next question comes from the line of Lee <unk> with Cantor Fitzgerald. Your line is now open.
Hey, Thanks for taking my question.
Maybe just a follow up for that.
Neil Okay cool or can you just clarify do these patients need to progress before they can cross over maybe just a little more color on the criteria for crossover and then can you come these patients in the total end to support the efficacy.
As well.
Alright.
Yes.
I can.
I can take that question.
Yes.
Patients treated with Allo NK IL two.
They're not responding.
That means if they are not showing a partial response or a complete response.
We'll have the opportunity to cross over to the combination treatment.
Now this brings me to your second question, whether these patients then could go cross over into the analysis cohorts 48 for the primary endpoint and the answer is no because there could be a bias. So what we are having is that we say they think crossover twist.
The combination of treatment and will be treated but not be part of this analysis for the primary endpoint.
Okay got it.
And then you mentioned earlier you have the first site open enrolling patients just can give us some sense in terms of how many sites do we need to fully enroll the right portion.
Andreas you wanted to.
Question.
Yeah.
I mean for the run in portion.
As you know there is.
Somewhat of a staggered approach, especially for the first three patients per cohort.
So our current assumption is that we probably need five to six good recruiting sites for the initial four.
Four cohorts and then we will bring more sites on board.
Study progresses, we'll continues but we are in an active process to add sites.
As we said we are on track to provide initial safety and efficacy data first half of 2024.
Okay. Thank you.
Okay.
Thank you one moment for our next question. Please.
Okay.
Our next question comes from the line of Diana <unk> with Leerink Partners. Your line is now open.
Two questions from me one on the new AP 101 arm.
Thank you had known that it was a possibility that FDA with one arm liked the contribution of components, but initially my understanding is.
Put it in the design because kols feedback that they were hesitant to enroll patients into such an arm.
The preclinical data, suggesting NK cells alone wouldn't have benefit I wonder how have your conversations gone with kols in sight.
What can you do to ensure enrollment.
And to this arm and enrollment overall with this study now that this arm as a possibility and then my second question is on <unk> 24.
And.
In.
Particularly in Egfr in lung cancer, but also across your indications a lot of interesting data with antibody drug conjugates and I wonder whether there is potential down the road after Easter benefit said combine with chemotherapy and that you are considering that and in the form of an ADC.
Going forward. Thank you.
Yes.
Yes, I can take both questions. So.
Yes, so hello, NK IL two arm.
You mentioned.
Isn't the arms that we added ultra after.
Discussion with some of our.
Clinical advisor key opinion leaders.
Probably the only way to make such an arm recruiting arm is what we'd implemented now.
We give patients the option if they do not have a response after cycle one they can immediately cross over to the combination treatment. So.
They will have the option to receive what we believe is a more active treatment and.
Again as I said, we believe it's a number of patients in this arm will be relatively small as we are not expecting to see a very high response rate here.
So this is I think a good compromise that most of our clinical sites belief is acceptable to patients.
If you would have an arm that has only allo NK cells with LTE auction to crossover I think you would have quite significant challenges to recruit in such environment.
S for AFM 24, yes, we have a number of indications, especially in the non small cell lung cancer field, where we do see adc's coming.
Up and we.
And we believe that the mechanism of action of <unk> from 24.
Could fit very well with was ADC. So combination of either with <unk> for example, in the Egfr mutant field or with Adcs postings in non small cell lung cancer Egfr windup in Egfr mutant fields are definitely options that we would look at after we've completed.
Our one or two study.
Great. Thank you.
Thank you one moment for our next question. Please.
Our next question comes from the line of <unk> <unk> with Wells Fargo. Your line is now open.
Great. Thanks for the questions.
Two questions on the AFM 13 program.
The first one is how how is the infusions of the NK and Sam <unk>.
Handled.
On the day of infusion I was wondering.
So this is not a pre complex.
Product.
Each component is infused firsthand what.
What is the space of time between the two infusions.
The second question is about how you select the two cohorts for stage two.
Would that be based on.
Two cohort.
Having to have the same NK component and paydowns or hadn't.
<unk> or these two cohorts having to have the same.
13 dose or it doesn't matter just the two cohorts with the best performing <unk>. Thank you.
Great.
Uh huh.
Yeah. So.
In terms of administration and then how is the trial currently is designed.
We start on the days, where we give a from a photo seem to make and.
NK cells with simply make infusion.
Initial infusion duration is four hours for the first cycle, but with the option to reduce C duration of infusion.
Infusion related reactions.
Then we have a one hour break and then we have the NK cell infusion, which usually is what.
It was a pretty short of 15 to 30 minute infusion.
This is based on the previous experience, especially with Rituxan.
Rituximab and B cell lymphomas, I think in all programs Rituximab, which gives them first to lower some of our.
Fusion of Rituximab throughout the body and then followed by the NK cells, which has quite well worked into the b cell field.
So this is houses the regimen would it be handled.
And second question was around selection of see appropriate.
Appropriate cohort.
Again, there is no precise specifications. So we do not necessarily have to use the same cell dose or is the same simply make dose into two cohorts.
We'll do a good assessment or our assessment of all the risk benefit profile, both looking at the efficacy and safety and based upon that we will select two most appropriate cohorts for the part two of the study.
Great. Thank you.
Thank you one moment for our next question. Please.
Our next question comes from the line of Brad <unk> with Stifel. Your line is now open.
Alright. Thanks for the question I had a two parter one of them was answered about your view on the durability when it comes to the accelerated approval previously.
On top of that I guess I want to ask do you expect the MD Anderson presentation, which I think will include the final follow up for the three to four cycle patients to be definitive demonstration of the durability of your potential commercial product or would you tell us to wait for the illuminate 200 III data to start rolling in thank you.
Okay.
Andrea.
Cool.
That's a very difficult question.
I think that's what we will show at Ash is clearly an update of course CFS or PFS.
Survival and overall survival.
Not to say this will be the final as we already indicated in the abstract there are still a quite significant number of patients in follow up so that.
Could it be for us a full update of what's supposed to even longer duration of responses or or survival.
Now how is the state of translate into the Lumina studies, a little bit more difficult to and so we believe that the 104 study is a very good proof of concept study, which I think indicates the magnitude of clinical effect that you could expect.
Based on all of our preclinical data we have shown is that C. L. O NK cell is a very active CT administration.
Is it all tends to be even a little bit more potent pre complexing again with the caveat that this is.
Preclinical data, but we released at 104 is probably a very good indicator of what can be achieved with an active CD 16 a positive.
NK cell and symptomatic.
Thank you.
Thank you one moment for our next question. Please.
Our next question comes from the line of Jin.
Jen with Laidlaw <unk> company. Your line is now open.
Good morning, and thanks for taking the question.
You have introduced.
So the concept or the phenomenon up double.
Refractory patient.
My question is does the.
Loopnet.
203 study.
Only improved pacing.
Presentation or this phenomenon or you will have.
Single refractory patients as well.
No. It can takes us all patients.
Our recruited into Lumi NYC has to be double refractory. So the requirements. They have at least phase one combination chemotherapy regimen. So you have failed BV NCI have failed PD. One. So if you will it's modest triple refractory. So it's chemotherapy refractory PD, one refractory NPV of refractory so.
This is a patient population where he believes he has absolutely no medical alternative for these patients are in dire need for active treatment.
Okay, that's very helpful and.
In terms of MD Anderson.
What coppola.
No.
Most of the patient also being categorized into this.
Category or some.
So single refractory patient so I just wanted to get some sense.
How to think about that data versus the future.
Readout you have in first half of next year.
So in the MD Anderson trial.
The patients with Hodgkin lymphoma, all fall into this category of tablet refractory. So all patients are of BV and PD one refractory.
As you all remember we also had a very small group of five patients of non Hodgkin lymphoma.
PD one is not approved for all non Hodgkin lymphomas, we have two patients in the non hodgkin lymphoma cohorts that have not been exposed to a PD, one but have been exposed to PV.
But again as at Corp populations, you Hodgkin lymphoma population all.
All patients has been double refractory to BV and checkpoint inhibitors.
Okay, Great that's very helpful and thanks, and congrats on the progress.
Yeah.
Thank you.
As a reminder to ask a question you will need to press star one one and please wait for your name to be announced one moment for our next question.
Question comes from the line of Sean Lee with H C. Wainwright. Your line is now open.
Good morning, guys and thanks for taking my question I was just wondering if you could provide a bit more color on what.
What type of data can we expect from <unk>.
Mentioned peaks like the first three cohorts.
Andrew.
Oh, sorry, I had a little bit of a disconnect can you repeat your question.
Sure I was just wondering if you can provide bema com the type of data you can expect from ash at four 5%.
<unk> 44 for the first three cohorts I think as you mentioned.
Yes.
24 will not be at ash, but will be a separate.
Disclosure, obviously data will happen in December or not as we said we have seen three cohorts which is.
Egfr wild type non small cell lung cancer gastric cancer and since the basket cohorts it was HCC pancreatic and biliary tract.
And we have about 10 to 15 varies a little bit from cohort to cohort.
Ponce valuable patients, where we will show.
Mainly response rates I think it's too early to.
Have a long term follow up data or as many of these patients were recruited over the last six months, but we should have quite robust response data from these three cohorts.
Got it thanks.
Yes.
Thank you.
I am currently showing no further questions at this time.
This concludes today's conference call. Thank you for your participation you may now disconnect everyone have a wonderful.
Okay.
Okay.
[music].
Okay.
Okay.
Okay.
[music].
Yes.
[music].